Coupe N, Schadendorf D, Danson S, et al. PACMEL: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in Advanced BRAF wild type melanoma. SMR 2017, abstract SMR05-2.
Gunstige langetermijnuitkomsten watch & wait-strategie bij rectumcarcinoom
aug 2018 | Maag-darm-leveroncologie